Cost-effectiveness of raltegravir in HIV/AIDS

Medicine & Life Sciences

• Raltegravir Potassium 100%
• Cost-Benefit Analysis 58%
• Acquired Immunodeficiency Syndrome 56%
• HIV 46%
• Costs and Cost Analysis 15%
• Salvage Therapy 11%
• HIV Infections 8%
• HIV Integrase Inhibitors 8%
• p31 integrase protein, Human immunodeficiency virus 1 7%
• Therapeutics 7%
• Pharmaceutical Economics 6%
• Reverse Transcriptase Inhibitors 5%
• Opportunistic Infections 5%
• Protease Inhibitors 5%
• Complementary Therapies 4%
• Health 4%
• Duration of Therapy 4%
• HIV-1 4%
• Antiviral Agents 4%
• Population 3%
• Weights and Measures 3%
• Mortality 2%
• Incidence 2%

Social Sciences

• AIDS 56%
• costs 38%
• scenario 14%
• economic model 11%
• time 10%
• Swiss 9%
• Clinical Practice 8%
• health 8%
• evaluation 8%
• mortality 8%